U.S. market Closed. Opens in 13 hours 46 minutes

SYRE | Spyre Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for SYRE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak.

Valuation (9%)

Company Industry
P/E Ratio (TTM) -8.32 -22.08
PEG Ratio (TTM) -0.11 15.66
P/S Ratio (TTM) 1,669.31 49.38
P/B Ratio (TTM) 4.13 18.85
P/FCF Ratio (TTM) -11.12 -3.07
Price to 5YR AVG Earnings Ratio N/A -3.42
Price to 5YR AVG FCF Ratio N/A -9.04

Profitability (0%)

Company Industry
ROA (TTM) -42.65% -5.15%
ROE (TTM) -159.89% 16.37%
Net Profit Margin (TTM) -17,848.46% -2,030.32%
ROIC 5YR AVG N/A 15.65%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 59.72% 24.24% N/A
Revenue -50.00% -29.19% N/A
Net Income 16.51% -4.03% N/A
Cash Flow -51.91% -11.81% N/A

Health (49%)

Company Industry
Current Ratio (TTM) 19.70 6.19
Quick Ratio (TTM) 19.70 5.91
D/E Ratio (TTM) N/A -15.10
Interest Coverage (TTM) N/A -1.60
Piotroski F-Score 2 5
Altman Z-Score 13.89 14.02
LTL to 5YR AVG FCF N/A 0.18
Shares Outstanding Growth 5YR AVG N/A 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙